



## Press release

### STADA launches medical cannabis for therapy of chronic pain patients

- As one of the largest pharmaceutical companies in Germany, STADA is now contributing to the care of chronic pain patients in particular with medical cannabis, thus offering a complementary therapy option.
- STADA CEO Peter Goldschmidt: "STADA is one of the first major pharmaceutical manufacturers to expand its portfolio with medical cannabis in Germany. In doing so, we are benefiting from our expertise in the field of specialty pharmaceuticals and are complementing this with a modern portfolio of patient-specific therapies."
- STADA Germany Head Eelco Ockers: "We are very pleased to be able to offer a patient-specific therapy option for chronic pain. With this, we would like to provide physicians with further treatments and products offering STADA's well-known quality."

**Bad Vilbel, March 8, 2021** – STADA is one of the largest pharmaceutical companies in Germany to launch medical cannabis on the market. STADAPHARM GmbH, which is responsible for the specialty business of STADA Group and has many years of experience in pain therapy, is now introducing its own product portfolio for this new form of therapy. Therapy with medical cannabis is primarily directed at chronic pain patients who suffer from pain or its side effects despite established medications such as opioids. Furthermore, medical cannabis can also be used for patients with spasticity in multiple sclerosis and other neurological and oncological therapy fields.

"STADA is one of the first leading pharmaceutical manufacturers to expand its portfolio with medical cannabis in Germany. In doing so, we are benefiting from our expertise in the field

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au



of specialty pharmaceuticals and are complementing this with a modern portfolio of patient-specific therapies," explains STADA CEO Peter Goldschmidt.

STADA's Head of Germany Eelco Ockers adds: "We are pleased to be able to offer a patient-specific therapy option for chronic pain. With this, we would like to provide physicians with further treatments and products offering STADA's well-known quality."

With this novel therapy option, STADA is strengthening its perception as a "Go-To-Partner" for doctors and pharmacists. In addition to support for current research and patient experience with medical cannabis, orientation in the prescription and reimbursement process is also to be created.

For patient-specific therapy, there will be a broad product portfolio.

Therapy with medical cannabis can be a suitable complement to conventional therapies.<sup>1</sup> To support doctors in finding the right option for patients, STADAPHARM is providing product-selection and dosage aids.

Accompanying this, STADAPHARM is offering a comprehensive range of services in terms of materials and targeted additional training for doctors and pharmacists.

A specially trained field force for medical cannabis is informing doctors about medical aspects as well as the practical use of medical cannabis, prescribing, applying for reimbursement by health insurance companies and individual patient treatment regimens. This is aimed at providing guidance and education in a relatively new market. These comprehensive and supportive measures round out STADA's offering, true to the group's purpose of "Caring for People's Health as a Trusted Partner".

---

<sup>1</sup> [Starke Schmerzmittel durch Cannabis ersetzen? | Infos von Experten](#). 31. August 2017, abgerufen am 15. Februar 2021



**About STADA Arzneimittel AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

***Additional information for journalists:***

STADA Arzneimittel AG  
Media Relations  
Stadastrasse 2-18  
61118 Bad Vilbel - Germany  
Phone: +49 (0) 6101 603-165  
Fax: +49 (0) 6101 603-215  
E-Mail: [press@stada.de](mailto:press@stada.de)  
Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

***Additional information for capital market participants:***

STADA Arzneimittel AG  
Investor & Creditor Relations  
Stadastrasse 2-18  
61118 Bad Vilbel – Germany  
Phone: +49 (0) 6101 603-4689  
Fax: +49 (0) 6101 603-215  
E-mail: [ir@stada.de](mailto:ir@stada.de)  
Or visit us on the Internet at [www.stada.com/investor-relations](http://www.stada.com/investor-relations)

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au